Advice

following a resubmission:

paliperidone palmitate prolonged release suspension for injection (Xeplion) is accepted  for use within NHS Scotland.

Indication under review: maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.  In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Paliperidone prolonged release suspension for injection was non-inferior to another atypical antipsychotic depot injection in terms of control of schizophrenia symptoms over a 3-month period and was more effective than placebo in preventing relapse of schizophrenia.

Download detailed advice128KB (PDF)

Download

Medicine details

Medicine name:
paliperidone palmitate (Xeplion)
SMC ID:
713/11
Indication:
For maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Central nervous system
Submission type
Resubmission
Status
Accepted
Date advice published:
07 November 2011